Multiple myeloma is fatal primarily because it dismantles several of the body’s critical systems at once. Cancerous plasma cells crowd out healthy bone marrow, cripple the immune system, damage the kidneys, and thicken the blood. The five-year survival rate is about 64%, and while modern treatments have extended life significantly, most patients eventually face complications from one or more of these cascading failures. Here’s what actually happens in the body.
Bone Marrow Gets Taken Over
Healthy bone marrow produces red blood cells, white blood cells, and platelets. In multiple myeloma, malignant plasma cells multiply and physically crowd out the normal cell-producing machinery. Studies comparing myeloma patients with and without severe blood count drops found that those with the worst counts had marrow packed with about 56% cancerous plasma cells, compared to 35% in those with more stable blood counts.
This takeover creates three dangerous shortages at once. Red blood cell production drops, causing anemia that starves tissues of oxygen and strains the heart. White blood cell production falls, leaving the body unable to fight infections. And platelet counts decline, impairing the blood’s ability to clot. That combination, sometimes called pancytopenia, accelerates the disease by making patients vulnerable to bleeding episodes and serious infections simultaneously. Symptoms can include persistent fatigue, unexplained fevers, bleeding gums, blood in the urine, and chronic nosebleeds.
The Immune System Collapses
Even before the marrow is fully overrun, myeloma cripples immune function in a more targeted way. Normal plasma cells are the body’s antibody factories, each one producing a different antibody to fight a different threat. Myeloma cells produce only one useless antibody (called a monoclonal protein or M-protein) in enormous quantities, while suppressing the production of all the functional antibodies you actually need.
The cancer also releases chemical signals that dial down the activity of other immune cells, making the entire defense network less responsive. The result is a profound vulnerability to infection. Myeloma patients face a significantly higher risk of pneumonia, bloodstream infections, meningitis, kidney infections, and bone infections. Viral threats increase too, particularly influenza and shingles. Even in the precancerous stage before full myeloma develops, the risk of bacterial bloodstream infection is roughly double that of a healthy person. Infection is one of the most common causes of death, accounting for about 4 to 6% of deaths depending on treatment history, and is often what ultimately ends a patient’s life when the disease becomes resistant to therapy.
How Myeloma Destroys the Kidneys
Kidney damage is one of the hallmarks of multiple myeloma, and it can become irreversible. The mechanism is specific: myeloma cells produce massive amounts of free light chains, which are fragments of the abnormal antibody. These light chains are small enough to pass through the kidney’s filters, but once inside the kidney’s drainage tubes (called tubules), they bind to a protein normally present there and form hard, obstructive casts.
These casts physically block the tubules, like debris clogging a pipe. They also trigger inflammation that damages the tubule walls directly. When the walls rupture, the surrounding kidney tissue becomes inflamed and scarred. Over time, this process, called cast nephropathy, can destroy enough of the kidney’s filtering capacity to cause organ failure. Patients in kidney failure face a sharply worse prognosis because the body can no longer clear waste products or regulate fluid balance, and dialysis adds its own risks and complications.
Blood Thickening and Circulation Problems
The flood of abnormal protein from myeloma cells can make the blood physically thicker than normal, a condition called hyperviscosity. When blood becomes too viscous, it struggles to flow through small vessels, and the consequences show up across multiple organs.
The classic warning signs are a triad: mucosal bleeding (nosebleeds from both nostrils, bleeding gums, gastrointestinal bleeding), vision problems (blurred vision, retinal hemorrhages, or blockage of the veins draining the eyes), and neurological symptoms (drowsiness, confusion, seizures, or loss of coordination). More severe cases can trigger cerebral hemorrhage, heart failure from the heart straining to pump thickened blood, and pulmonary hypertension causing shortness of breath. While hyperviscosity itself doesn’t appear to shorten overall survival on its own, acute episodes can be medical emergencies that cause strokes or organ damage if not treated quickly.
Bone Destruction and Hypercalcemia
Myeloma cells don’t just sit in the bone marrow. They actively stimulate the cells that break down bone while suppressing the cells that rebuild it. This creates the painful bone lesions that many patients experience, particularly in the spine, ribs, pelvis, and skull. Beyond the pain and fracture risk, this constant bone breakdown floods the bloodstream with calcium.
Excess calcium in the blood, called hypercalcemia, disrupts the electrical signals that control the heart, kidneys, and brain. It causes confusion, extreme thirst, nausea, constipation, and cardiac rhythm disturbances. Left untreated, severe hypercalcemia can cause kidney shutdown, coma, and cardiac arrest. It’s one of the more acute, immediately life-threatening complications of myeloma.
Heart Disease and Treatment Toxicity
Heart disease is a significant cause of death in myeloma patients, responsible for roughly 3 to 6% of deaths. The connection runs through multiple pathways: the disease itself causes anemia that forces the heart to work harder, kidney dysfunction raises blood pressure and fluid retention, and some of the treatments used to fight myeloma carry cardiovascular side effects. Myeloma patients have higher rates of cardiovascular disease than people of the same age without cancer.
Treatment toxicity also contributes to mortality in another way. About 7% of myeloma patients who undergo stem cell transplant and 6% of those who don’t will die from a separate, second cancer. Some of the drugs used to treat myeloma, particularly when combined with transplant, increase the risk of developing blood cancers like acute myeloid leukemia or a precancerous marrow condition. In clinical trials, roughly 10% of patients developed a second primary cancer regardless of whether they received transplant, though the types of second cancers differed between treatment approaches.
How These Complications Interact
What makes myeloma particularly dangerous is that these problems don’t happen in isolation. They compound each other. A patient whose marrow is failing produces fewer white blood cells, making them vulnerable to infection. At the same time, their kidneys may be deteriorating, which limits the body’s ability to handle the stress of that infection. Anemia strains the heart, and the heart is already dealing with thickened blood and calcium imbalances. Each system failure makes the others harder to manage.
Most patients don’t die from the cancer cells themselves in the way a solid tumor might kill by compressing a vital organ. Instead, myeloma gradually erodes the body’s support systems until one of them fails critically, whether that’s an overwhelming infection the immune system can’t fight, kidneys that stop filtering, a heart that can’t keep up, or uncontrolled bleeding the body can’t clot. The specific cause varies from patient to patient, but the underlying pattern is the same: the cancer undermines so many systems that the body eventually loses the capacity to recover from a complication that a healthy person would survive.